CL2020003324A1 - Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos. - Google Patents

Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.

Info

Publication number
CL2020003324A1
CL2020003324A1 CL2020003324A CL2020003324A CL2020003324A1 CL 2020003324 A1 CL2020003324 A1 CL 2020003324A1 CL 2020003324 A CL2020003324 A CL 2020003324A CL 2020003324 A CL2020003324 A CL 2020003324A CL 2020003324 A1 CL2020003324 A1 CL 2020003324A1
Authority
CL
Chile
Prior art keywords
methods
compositions
disorders
treatment
activation
Prior art date
Application number
CL2020003324A
Other languages
English (en)
Inventor
Gregory A Demopulos
Thomas Dudler
Bo Nilsson
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of CL2020003324A1 publication Critical patent/CL2020003324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En un aspecto, la invención proporciona composiciones y métodos para prevenir, reducir, y/o tratar una enfermedad, trastorno o afección asociado con activación inducida por fibrina del sistema del complemento y la activación asociada de los sistemas de coagulación y/o contacto que comprenden administrar una cantidad terapéutica de un anticuerpo inhibidor de MASP-2 a un sujeto que necesita del mismo. En algunas modalidades, los métodos de la invención proporcionan anticoagulación y/o antitrombosis y/o antitrombogénesis sin afectar la hemostasia. En una modalidad de este aspecto de la invención, las composiciones y métodos son útiles para tratar a un sujeto que padece de, o está en riesgo de desarrollar, una enfermedad, trastorno o afección asociada con inflamación relacionada con el complemento, coagulación excesiva o activación del sistema de contacto iniciada por fibrina o plaquetas activadas.
CL2020003324A 2018-06-22 2020-12-21 Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos. CL2020003324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688611P 2018-06-22 2018-06-22

Publications (1)

Publication Number Publication Date
CL2020003324A1 true CL2020003324A1 (es) 2021-04-23

Family

ID=68984236

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003324A CL2020003324A1 (es) 2018-06-22 2020-12-21 Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.

Country Status (18)

Country Link
US (3) US20200140570A1 (es)
EP (1) EP3836965A4 (es)
JP (1) JP2021527698A (es)
KR (1) KR20210024003A (es)
CN (1) CN112638417A (es)
AU (2) AU2019288459B2 (es)
BR (1) BR112020025841A2 (es)
CA (1) CA3104083A1 (es)
CL (1) CL2020003324A1 (es)
EA (1) EA202190106A1 (es)
GE (3) GEP20257785B (es)
IL (1) IL279588A (es)
JO (1) JOP20200328A1 (es)
MA (1) MA53234A (es)
MX (1) MX2020013755A (es)
PH (1) PH12020552188A1 (es)
SG (1) SG11202012627UA (es)
WO (1) WO2019246367A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI834025B (zh) * 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
CN120173118B (zh) * 2020-12-16 2025-09-16 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
TW202305010A (zh) * 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
CA3221859A1 (en) * 2021-06-08 2022-12-15 Xiaowu Liu Anti-masp-2 antibody and use thereof
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
WO2023173036A2 (en) * 2022-03-10 2023-09-14 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
CN115125299A (zh) * 2022-08-09 2022-09-30 大连珍奥药业股份有限公司 Masp1在筛选预防和/或治疗心血管疾病的药物中的应用
EP4626891A1 (en) 2022-11-30 2025-10-08 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
ES2631127T3 (es) * 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1810979B1 (en) * 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
BR112014031522A2 (pt) * 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
US20150353623A1 (en) * 2014-04-03 2015-12-10 Loma Linda University Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases
AU2016354117B2 (en) * 2015-11-09 2019-11-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation

Also Published As

Publication number Publication date
CN112638417A (zh) 2021-04-09
AU2019288459A1 (en) 2021-02-04
AU2026200868A1 (en) 2026-02-26
GEAP202515541A (en) 2025-03-10
JP2021527698A (ja) 2021-10-14
EA202190106A1 (ru) 2021-04-13
IL279588A (en) 2021-03-01
MX2020013755A (es) 2021-05-12
GEP20267851B (en) 2026-01-26
AU2019288459A2 (en) 2021-03-18
US20200140570A1 (en) 2020-05-07
EP3836965A4 (en) 2022-04-20
GEP20257785B (en) 2025-08-11
JOP20200328A1 (ar) 2020-12-15
AU2019288459B2 (en) 2025-11-13
KR20210024003A (ko) 2021-03-04
US20230212314A1 (en) 2023-07-06
SG11202012627UA (en) 2021-01-28
WO2019246367A1 (en) 2019-12-26
MA53234A (fr) 2022-04-20
CA3104083A1 (en) 2019-12-26
US20260062499A1 (en) 2026-03-05
BR112020025841A2 (pt) 2021-03-23
PH12020552188A1 (en) 2021-06-28
EP3836965A1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
CL2020003324A1 (es) Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
MX2023008368A (es) Uso de antagonista de il-33 o un antagonista de il-4r en la fabricacion de un medicamento para tratar enfermedades o trastornos inflamatorios.
MX2020010469A (es) Inhibidores del atf6 y sus usos.
EA202090641A1 (ru) Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
EA202091965A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 ИЛИ ДВОЙНОГО ИНГИБИТОРА Bcl-2/Bcl-xL И ИНГИБИТОРА BTK И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2018008331A (es) Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
CL2019003789A1 (es) Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.
EP3368560A4 (en) CPG REDUCED FACTOR VIII VARIATIONS, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASIS
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
CL2022001708A1 (es) Decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
PE20180556A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
EP3755278A4 (en) RESORBABLE INTRAVASCULAR DEVICES FOR TREATMENT OF VEIN OCCLUSION
MX2020008146A (es) Proteinas anticoagulantes y su uso para tratar enfermedades asociadas a la activacion de neutrofilos.
MX2021000601A (es) Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
CL2024001421A1 (es) Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.
MX375272B (es) Ciclodextrinas como procoagulantes